Exploring the Potential of Creatine in Alleviating Depression Symptoms

Creatine, a well-known supplement acclaimed for enhancing athletic performance, is now under scrutiny for its possible effects on mental health, specifically depression. Recent research published in Brain Medicine delves into creatine's role in alleviating depressive symptoms by potentially meeting the brain's energy demands.

The study provides an intriguing yet cautious perspective on the subject, revealing that while some trials suggest positive outcomes, others do not show similar benefits, creating a mosaic of uncertainty rather than definitive conclusions. The review was orchestrated by Bassam Jeryous Fares of the University of Ottawa, who, alongside his team, sifted through existing studies rather than launching new trials.

Researchers identified six pertinent studies that encompassed five randomized controlled trials involving a total of 238 participants—126 receiving creatine and 112 on a placebo. The participant pool averaged 36 years in age, with a significant representation of women. Notably, two trials included only women.

Varied Results Among Trials

Four of the trials concentrated on individuals with major depressive disorder, while one examined participants with bipolar disorder undergoing depressive episodes. The differences in study design meant that researchers abstained from aggregating results into a single statistical analysis; instead, they evaluated each trial on its own merits.

Among the trials, two demonstrated substantial improvements in those taking creatine, particularly among women. One study indicated that participants who supplemented with five grams of creatine alongside the antidepressant escitalopram experienced notable reductions in depressive symptoms over eight weeks, surpassing those on escitalopram alone. This improvement achieved a significant effect size, with a Cohen's d of 1.13 on the Hamilton Depression Rating Scale, and an increased rate of remission.

Additionally, another trial that integrated creatine with cognitive behavioral therapy noted better symptom relief compared to those who received therapy with a placebo. However, the remaining trials yielded disappointing results, revealing no meaningful improvements with either five or ten grams of creatine daily, particularly in populations that had previously not responded to other medications.

Safety Concerns and Further Avenues for Research

Importantly, researchers flagged a potential safety issue, as two participants with bipolar disorder exhibited signs of hypomania or mania after taking creatine, underscoring the possibility of varied responses based on underlying conditions.

The rationale for considering creatine's role in mental health revolves around the high-energy needs of the brain. Known primarily for its ability to replenish adenosine triphosphate (ATP) in muscles, creatine is also crucial for maintaining energy levels in brain cells. Previous investigations have suggested alterations in brain creatine metabolism in individuals with mood disorders, sparking interest in the relationship between cellular energy and depression.

Moreover, there's speculation that creatine might influence mood-regulating neurotransmitters like dopamine and serotonin, which are commonly targeted by antidepressants. Despite these associations, the authors of the review cautioned that much of this understanding is still theoretical, highlighting that current studies provide correlations rather than causal evidence linking creatine metabolism to depression.

"The signal is interesting, but it's not a verdict," Fares articulated, emphasizing the lack of consensus within the data due to the mixed results from the trials. Nicholas Fabiano, another co-author and psychiatry resident, echoed the need for circumspection, acknowledging that while creatine appears safe, established efficacy in treating depressive symptoms remains unverified.

Call for Expanded Research

The limited scope of current studies has faced criticism, particularly regarding sample sizes and gender disparity, as participants skewed towards female subjects—factors that could adversely affect the generalizability of the findings. Of the five trials, only two exhibited a low risk of bias, further complicating the validity of the results.

To strengthen the evidence base, researchers advocate for larger, more extensive clinical trials lasting beyond eight weeks. They propose investigating the effects of creatine alongside exercise while also assessing varied dosages to ascertain if higher amounts yield better results. Animal studies indicate that responses to creatine's effects might differ based on gender, a consideration that could explain why trials predominantly involving women exhibited the most favorable outcomes.

For the present, creatine stands as a fascinating area of inquiry rather than an established treatment for depression. Originally celebrated for its advantages in muscle development, it is now catching the attention of scientists seeking new pathways in mental health interventions.

The complete peer-reviewed study titled "Creatine as a treatment for depression" will be available through Open Access starting June 30, 2026, in Brain Medicine.